These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36043427)

  • 1. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H
    Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X; Zhang G; Wang J; Bi J
    Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 10. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
    Hara S; Mori K; Fukuokaya W; Tomomasa N; Oguchi T; Takahashi Y; Saito S; Katami J; Sano T; Kadena S; Hashimoto M; Yata Y; Nishi E; Suhara Y; Takamizawa S; Kurawaki S; Suzuki H; Miyajima K; Iwatani K; Urabe F; Ito K; Yanagisawa T; Tsuzuki S; Shimomura T; Kimura T
    Int J Clin Oncol; 2024 Aug; 29(8):1191-1197. PubMed ID: 38769191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
    Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
    Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
    Tartarone A; Lerose R; Tartarone M
    Med Oncol; 2022 May; 39(7):107. PubMed ID: 35553247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
    Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
    J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-metastatic castration-resistant prostate cancer: management recommendations.
    Alcaraz Asensio A; Alvarez Ossorio JL; Cozar Olmo JM; Chantada Abal V; Juarez Soto A; Linares Espinos E; Moreno Jimenez J; Muñoz Rodriguez J; Perez Fentes D; Plata Bello A; Rodrigo Aliaga M; Unda Urzaiz M; Vilaseca A
    Actas Urol Esp (Engl Ed); 2022 May; 46(4):193-213. PubMed ID: 35305957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.